The Patient-Reported Outcomes Project of HCV-TARGET (PROP up TARGET)

Project: Research project


Newer, more effective antiviral regimens for chronic hepatitis C viral (HCV) infection were recently approved. For the first time, patients and clinicians will have several treatment options from which to choose. Deciding which treatment to choose may prove challenging to patients and providers, as regimens will differ by cure rate, treatment harms, out-of-pocket costs, and other key patient-centered outcomes (PCOs). Data collected from clinical drug trials do not provide all the answers, nor do their data represent the broad spectrum of patients who will be treated in real-world clinical practice. Meanwhile, HCV-TARGET is the largest international research network and clinical registry of HCV patients and provides a unique opportunity to evaluate PCOs in a broad spectrum of patients being treated in real world clinical settings. We propose the Patient-Reported Outcomes Project affiliated with HCV-TARGET (“PROP up TARGET), which will leverage the pre-existing infrastructure and resources to integrate patient-centered outcomes research into HCV-TARGET. The specific aims of PROP up TARGET include: Aim 1: During treatment, we will compare SOF/LED versus ABT on the following treatment harms: toxicity, treatment-related symptoms, functional status, and out-of-pocket costs. Aim 2: Post-treatment, we will compare the two treatment regimens in terms of harms and benefits: cure rate, treatment-related symptoms, functional status.PATIENT OUTCOMES A patient engagement group and data derived from 45 patient interviews identified the top priority PCOs that will impact patient decision-making. PROP up TARGET is committed to providing this information to help patients and their providers make more informed treatment decisions
Effective start/end date8/1/1510/31/18


  • Patient-Centered Outcomes Research Institute (PCORI)


Hepatitis C
Health Expenditures
Patient Reported Outcome Measures
Patient Outcome Assessment
Patient Participation
Chronic Hepatitis C
Virus Diseases
Antiviral Agents
Decision Making
Clinical Trials